September 20, 2023
1 min watch
Save
VIDEO: Efficacy, safety of biosimilars discussed at ASRS annual meeting
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
SEATTLE — In this video, Esther M. Bowie, MD, discusses findings presented at the ASRS annual meeting on the efficacy and safety of ranibizumab biosimilars. The study, which evaluated 3,964 patients, was presented by Carl C. Awh, MD, FASRS.
“Basically, he showed they were able to maintain visual acuity with no serious side effects, no inflammatory effects, so that was interesting,” Bowie said.
In addition, Bowie discussed phase 3 findings presented by Min Sagong, MD, PhD, on SB15, an aflibercept biosimilar, after 1 year of treatment in patients with neovascular age-related macular degeneration.
References:
- Awh C, et al. Efficacy and safety of biosimilar ranibizumab-nuna and ranibizumab-eqrn in clinical use by a consortium of retina specialists. Presented at: American Society of Retina Specialists annual meeting; July 28-Aug. 1, 2023; Seattle.
- Sagong M, et al. Phase III randomized clinical trial comparing SB15 with reference aflibercept in neovascular age-related macular degeneration: 56-week results. Presented at: American Society of Retina Specialists annual meeting; July 28-Aug. 1, 2023; Seattle.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Bowie reports no relevant financial disclosures.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.